How many cycles of cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy should be administered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CAP Chemotherapy Cycle Recommendation

The evidence does not support the use of CAP (cyclophosphamide, doxorubicin, and cisplatin) chemotherapy for any indication where it would be considered standard of care. The provided guidelines and FDA labeling do not recommend CAP as a preferred regimen for any cancer type.

Context and Evidence Analysis

What the Guidelines Actually Recommend

The NCCN guidelines 1 for ovarian cancer—the only malignancy where CAP has been historically studied—do not list CAP as a recommended regimen. Instead, they recommend:

  • Paclitaxel/carboplatin combinations (Category 1) for 6 cycles
  • BEP (bleomycin, etoposide, cisplatin) for malignant germ cell tumors: 3 cycles for good risk, 4 cycles for poor risk 1

The 2025 ASCO guideline for neoadjuvant ovarian cancer 2 recommends ≤4 cycles of NACT before interval cytoreductive surgery, with a total of 6 cycles (NACT plus post-ICS), but again does not mention CAP.

FDA Labeling for Cisplatin

The FDA label for cisplatin 3 specifies dosing for metastatic ovarian tumors in combination with cyclophosphamide (not the full CAP regimen):

  • Cisplatin 75-100 mg/m² IV once every 4 weeks
  • Cyclophosphamide 600 mg/m² IV once every 4 weeks

This is a 2-drug regimen (CP), not CAP. The FDA label does not recommend adding doxorubicin.

Research Evidence on CAP

The research studies reveal why CAP is not recommended:

Ovarian Cancer:

  • A 1992 randomized trial 4 comparing 5 vs 10 cycles of CAP found no survival difference (P=0.41), with 5 cycles being less toxic
  • Complete response rates were only 34-35% at second-look laparotomy
  • The study concluded CAP5 is preferable to CAP10 due to equal efficacy but less toxicity

Other Malignancies:

  • Lung cancer studies 5, 6 showed no survival benefit for CAP vs no treatment in stage I NSCLC
  • Only 53% of patients completed all 4 cycles due to poor compliance and toxicity
  • The authors concluded CAP "should not be recommended" for resected early-stage lung cancer

Clinical Decision Algorithm

If You Are Considering CAP:

  1. Stop and reconsider the indication

    • CAP is not a guideline-recommended regimen for any cancer type in 2025
    • Modern platinum-taxane doublets have replaced CAP in ovarian cancer
  2. For ovarian cancer specifically:

    • Use paclitaxel/carboplatin for 6 cycles (Category 1) 1
    • For neoadjuvant treatment: ≤4 cycles before surgery, then complete 6 total cycles 2
  3. If CAP must be used (historical protocol or resource-limited setting):

    • Based on the only positive comparative data: 5 cycles maximum 4
    • Dosing: Cyclophosphamide 600 mg/m², doxorubicin 40 mg/m², cisplatin 100 mg/m² every 4 weeks
    • Expect only 53% completion rate and significant toxicity

Critical Caveats

  • Myelosuppression is severe: Grade 3-4 leukopenia in 69% of patients, with frequent nadir fever requiring hospitalization 4
  • Renal toxicity: Median creatinine elevation is significant 4
  • Peripheral neuropathy is common and cumulative 4
  • Poor compliance: Only 53-57% of patients complete planned therapy 5, 6
  • Cardiac toxicity: Doxorubicin adds cumulative cardiotoxicity risk without proven benefit over CP alone

Bottom Line

Do not use CAP. If treating ovarian cancer, use paclitaxel/carboplatin for 6 cycles 1. If you inherited a patient on CAP from a historical protocol, the evidence supports 5 cycles maximum 4, but strongly consider switching to guideline-concordant therapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.